Table 3 Survival analyses
Number of cases | Months of follow-up (mean) | Number of events (recurrences) | Months until recurrence (mean) | p value* | |
|---|---|---|---|---|---|
T stage | 0.538 | ||||
T1–T2 | 13 | 22.0 | 5 | 20.6 | |
T3–T4 | 15 | 29.8 | 4 | 19.3 | |
CD66b index in invasive front | 0.691 | ||||
High | 13 | 24.5 | 4 | 12.5 | |
Low | 15 | 35.6 | 5 | 26.0 | |
CD66b index in intratumoural region | 0.879 | ||||
High | 14 | 30.3 | 4 | 18.8 | |
Low | 14 | 28.1 | 5 | 21.0 | |
CD66b/CD3 ratio in invasive front | 0.600 | ||||
High | 14 | 22.2 | 4 | 10.3 | |
Low | 14 | 36.2 | 5 | 27.8 | |
CD66b/CD3 ratio in intratumoural region | 0.757 | ||||
High | 14 | 24.8 | 3 | 13.7 | |
Low | 14 | 33.6 | 6 | 23.2 | |